Acyl-CoA:Lysocardiolipin Acyltransferase 1 and Age-Related Diseases: Comparison
Please note this is a comparison between Version 3 by Jun Zhang and Version 4 by Jason Zhu.

Cardiolipin (CL) is a mitochondrial signature phospholipid that plays a pivotal role in mitochondrial dynamics, membrane structure, oxidative phosphorylation, mtDNA bioenergetics, and mitophagy. The depletion or abnormal acyl composition of CL causes mitochondrial dysfunction, which is implicated in the pathogenesis of aging and age-related disorders. However, the molecular mechanisms by which mitochondrial dysfunction causes age-related diseases remain poorly understood. Studies in the field has identified acyl-CoA: lysocardiolipin acyltransferase 1 (ALCAT1), an acyltransferase upregulated by oxidative stress, as a key enzyme that promotes mitochondrial dysfunction in age-related diseases. ALCAT1 catalyzes CL remodeling with very-long-chain polyunsaturated fatty acids, such as docosahexaenoic acid (DHA). Enrichment of DHA renders CL highly sensitive to oxidative damage by reactive oxygen species (ROS). Oxidized CL becomes a new source of ROS in the form of lipid peroxides, leading to a vicious cycle of oxidative stress, CL depletion, and mitochondrial dysfunction. Consequently, ablation or the pharmacological inhibition of ALCAT1 have been shown to mitigate obesity, type 2 diabetes, heart failure, cardiomyopathy, fatty liver diseases, neurodegenerative diseases, and cancer.

  • ALCAT1
  • cardiolipin
  • aging
  • age-related diseases
  • mitochondria
  • mitochondrial dysfunction

1. Cardiolipin (CL) Remodeling and Acyl Composition

Cardiolipin (CL) is the only phospholipid with four acyl chains, which, in theory, can generate millions of CL species (1 × 420–40). However, the four fatty acyl chains of CL are restricted to C18 chains dominated by the linoleoyl group (C18:2) in the heart, skeletal muscle, and liver [16,17,18,22]. This unique fatty acyl composition, also known as tetralinoleoyl CL (TLCL), plays an important role in the maximum efficiency of respiration. The hydrophobic double-unsaturated linoleic diacylglycerol species is believed to be required for the high-affinity binding of CL to proteins, whereas TLCL is required for mitochondrial membrane structure in the heart [23]. Thus, an alteration in the molecular species composition of CL affects the activities of cytochrome c oxidase and other electron transport chain enzymes [24,25]. However, the formation of this unique fatty acyl composition of CL does not occur during de novo biosynthesis because the enzymes of the CL biosynthetic pathway lack appropriate substrate selectivity [26,27,28]. This is further confirmed by the studies on human CL synthase [29,30,31]. Thus, newly synthesized CL is believed to undergo a remodeling process to achieve its appropriate acyl content.
Two distinct mechanisms have been posited to carry out the CL remodeling process in mammals (Figure 1) [15,32,33,34]. The first mechanism involves transacylation of acyl groups from phosphatidylcholine (PC) or phosphatidylethanolamine (PE) to CL, which is partly catalyzed by tafazzin (TAZ), a transacylase enzyme that when mutated causes defective CL remodeling and Barth syndrome (BTHS) [19]. The alternative pathway involves deacylation by phospholipase A2 to lysocardiolipin, followed by reacylation to CL by two acyl-CoA-dependent lysocardiolipin acyltransferases. The first acyltransferase is the acyl-CoA:lysocardiolipin acyltransferase (ALCAT1) which catalyzes the remodeling of CL with both monolysocardiolipin (MLCL) and dilysocardiolipin as substrates at the mitochondrial associated membrane [18,20]. The second acyltransferase is an MLCL acyltransferase (MLCLAT), which catalyzes the synthesis of CL with MLCL as the substrate [35]. Intriguingly, MLCLAT shares the same sequence homology with the mitochondrial trifunctional protein, which is localized at the inner mitochondrial membrane [21,36]. In comparison to the MLCLAT, which catalyzes exclusively the synthesis of TLCL by using linoleoyl-CoA and MLCL as substrates, ALCAT1 lacks a preference for linoleic acid as a substrate [20,21]. Consequently, CL remodeling by ALCAT1 with very-long-chain fatty acids, such as docosahexaenoic acid (DHA) and arachidonic acid, leads to TLCL deficiency, oxidative stress, and mitochondrial dysfunction, which is implicated in the pathogenesis of various age-related diseases [17,18,37,38,39]./media/item_content/202206/62abd02c48622cells-11-01906-g002.png
Figure 1. Proposed CL remodeling pathways in obesity and aging. Figure 1. Proposed CL remodeling pathways in obesity and aging. Aging and obesity causes oxidative stress, leading to the production of ROS. CL oxidation by ROS triggers the remodeling of its fatty acyl chains, which begins with hydrolysis of oxidized CL by phospholipase A2 (cPLA2), followed by acylation of lysocardiolipin by either tafazzin (TAZ), MLCLAT, or ALCAT1. TAZ is a transacylase that catalyzes physiological remodeling of CL with other phospholipids, such as PC and PE, whereas MLCLAT catalyzes remodeling of CL with MLCL and linoleoyl-CoA, leading to mitochondrial recovery. ALCAT1 catalyzes remodeling of CL with both MLCL or dilysocardiolipin and docosahexaenoic-CoA (C22:6) as substrates, leading to CL peroxidation by ROS and mitochondrial dysfunction.

2. Diabetes and Obesity

Obesity and T2DM are characterized by systemic oxidative stress, which is believed to be a principal causative factor of insulin resistance and other obesity-related metabolic complications [66,67,68,69,70]. Diabetes and obesity also cause a CL deficiency and the profound remodeling of CL’s acyl composition [15,18,22]. In support of the causative role of ALCAT1 in the pathogenesis of T2DM and obesity, ALCAT1 mRNA levels were upregulated by oxidative stress and diet-induced obesity (DIO). The stable overexpression of ALCAT1 in C2C12 skeletal myocytes led to CL depletion, the enrichment of DHA content in CL, severe oxidative stress, mitochondrial swelling, and a loss of cisterna structure [18]. Consequently, the targeted deletion of the ALCAT1 gene not only prevented the onset of DIO but also insulin resistance in metabolic tissues. ALCAT1 deficiency also significantly increased TLCL content in the heart, leading to significant improvement in mitochondrial complex I activity [18]. Additionally, ablation of ALCAT1 significantly attenuated ROS production, mtDNA depletion, and mtDNA mutation rate in response to oxidative stress. Moreover, ALCAT1 deficiency also prevented mitochondrial fragmentation and swelling by upregulating the expression of MFN2, a mitochondrial GTPase required for the fusion of the inner mitochondrial membrane [18,47].

3. Fatty Liver Disease

Obesity significantly increases the incidence of nonalcoholic fatty liver disease (NAFLD), yet the underlying connection remains poorly identified. Consistent with its projected role in obesity, ALCAT1 also plays a major role in the pathogenesis of NAFLD. ALCAT1 expression is upregulated in the liver in response to the onset of DIO. Accordingly, targeted deletion of the ALCAT1 gene prevented the onset NAFLD in response to DIO. Diet-induced NAFLD also caused mitochondrial fragmentation by downregulating the expression of MFN2 [33]. ALCAT1 deficiency prevented mitochondrial fragmentation in hepatocytes, in part by restoring MFN2 expression. Moreover, ALCAT1 deficiency also restored mitophagy, mtDNA copy number, and mtDNA fidelity, leading to significant improvement in mitochondrial respiration in the hepatocytes [33].

4. Heart Diseases

Heart disease remains the single largest cause of mortality in developed nations. Although major progress has been made in recent years in the prevention and treatment of cardiovascular diseases, there is still a lack of effective treatment for heart failure [71]. The mammalian heart is enriched with mitochondria, and therefore is one of the most sensitive organs to mitochondrial dysfunction [72,73]. ALCAT1 is most abundantly expressed in the heart and plays a key role in cardiomyopathy and heart failure by promoting TLCL deletion. Accordingly, targeted deletion of the ALCAT1 gene prevented the onset of cardiomyopathy associated with hyperthyroidism and heart failure in mice with myocardial infarction (MI) [17,37]. ALCAT1 deficiency also mitigated myocardial inflammation, fibrosis, and apoptosis in MI mice [17]. In support of key role of ALCAT1 in mitochondrial etiology of heart diseases, ALCAT1 protein expression in the heart was potently upregulated by MI. Consequently, treatment of MI mice with Dafaglitapin (Dafa), a very potent and highly selective ALCAT1 inhibitor, not only restored mitochondrial function but also effectively mitigated MI-induced left ventricle hypertrophy, fibrosis, and contractile dysfunction [17].
CL was initially discovered in the heart and therefore plays a pivotal role in cardiac health [74]. TLCL is the signature CL species in the heart and plays a key role in maintaining normal cardiac function by supporting mitochondrial membrane structure and activities of key enzymes involved in oxidative phosphorylation [15,16]. Consequently, TLCL depletion is implicated in the pathogenesis of various form of heart diseases, including dilated cardiomyopathy, heart failure, and BTHS [11,14,15]. However, the underlying causes for TLCL depletion in heart diseases remain to be identified. Additionally, the onset of heart diseases is associated with pathological remodeling of CL with DHA and other very long chain PUFA [18]. Enrichment of DHA not only renders CL highly sensitive to ROS production and lipid peroxidation in age-related diseases [15,57,75,76,77,78,79], but also leads to the development of cardiac dysfunction by impairing mitochondrial complex I activity during ischemia/reperfusion [11,12]. In further support of ALCAT1 in the mitochondrial etiology of MI, ablation or the pharmacological inhibition of ALCAT1 by Dafa not only restored TLCL levels, but also significantly decreased DHA content in CL in the heart. Consistent with the notion that increased DHA content promotes CL peroxidation, ablation or the inhibition of ALCAT1 by Dafa also prevented ROS production and lipid peroxidation, leading to an increased level of mtDNA copy number sand the restoration of mitochondrial respiration in the hearts of MI mice [17].
As one of the highest oxygen consuming organs in the body, the heart is highly sensitive to damage caused by hypoxia as a consequence of coronary artery blockage. Hypoxia causes oxidative stress, inflammation, and apoptosis of cardiomyocytes, all of which are implicated in the pathogenesis of heart failure. Consistent with predominant expression in microvascular tissues, ALCAT1 also plays an important role in mediating hypoxic response in the heart [64]. Accordingly, the stable overexpression of ALCAT1 in H9c2 cardiomyocytes mimicked the effect of hypoxia by up-regulating the expression of HIF-1α, a key transcription factor and regulator of hypoxic response [17]. Conversely, ALCAT1 deficiency or inhibition by Dafa significantly attenuated HIF-1α protein expression in cardiomyocytes, leading to significant attenuation of myocardial inflammation and apoptosis by decreasing the expression of TXNIP, NLRP3, Bax, and cleaved caspase-3 in the heart. Furthermore, ALCAT1 stimulated HIF-1α protein expression in part through oxidative stress, but not by stabilization of HIF- 1α protein through inhibition of prolyl hydroxylases (PHD) or ubiquitin-proteasome pathways. Accordingly, treatment of cardiomyocytes with Dafa or Mito-Q, a mitochondrial targeted antioxidant, significantly attenuated HIF-1α expression in response to hypoxia.

5. Neurological Diseases

Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of neurodegenerative diseases and contribute to the development of Parkinson’s and Alzheimer’s diseases [81,82,83]. In contrast to insulin-sensitive tissues, such as skeletal muscle and the heart, TLCL is not the predominant form of CL species in the brain, representing less than 5% of the total CL [84]. In contrast, CL from a mouse brain is dominated by long-chain PUFA, including DHA (C22:6) and arachidonic acids (C20:4), which contribute to 40% of the acyl side chains of CL [84,85]. Although the biological significance of this acyl composition remains elusive, the high content in PUFA likely increases uncoupling of mitochondrial respiration, leading to increased heat production, which plays an important role in maintaining normal brain function. However, the high content of DHA or other PUFA also renders CL extremely sensitive to oxidative damage in the brain, which may offer an explanation as to why the brain is so sensitive to mitochondrial dysfunction associated with aging. Consequently, traumatic brain injury has been shown to selectively increase the content of DHA in CL and cause CL peroxidation [86]. This selective CL peroxidation preceded the peroxidation of other phospholipids and the onset of apoptosis [86].
Oxidative damage to CL leads to the exposure of oxidized CL to the outer mitochondrial membrane, which serves as a recognition signal for mitophagy [14]. CL externalization to outer mitochondrial membrane is also implicated in the pathogenesis of neurodegenerative diseases. For example, CL externalization to outer mitochondrial membrane leads to mitochondrial dysfunction and α-synuclein aggregation, a key pathogenic event in neurodegenerative diseases [87]. Accordingly, mice with the targeted inactivation of the presynaptic protein α-synuclein exhibited a CL deficiency and a reduction in both TLCL content and the mitochondrial complex I/III activity of the electron transport chain [85]. The knockout mice also exhibited a deficiency of PG, the precursor for CL synthesis. In support of the causative role of ALCAT1 in the pathogenesis of neurodegenerative diseases, ALCAT1 deficiency or inhibition not only prevented MPTP induced Parkinson’s disease but also significantly attenuated the aggregation of α-synuclein, leading to significant improvement in mitochondrial morphology, respiration, and oxidative stress in the brains of a mouse model of Parkinson’s disease [38].

6. Bath Syndrome

One of the best examples that underscore the importance of CL remodeling in metabolic diseases is BTHS, an X-linked recessive disorder manifested by cardiomyopathy, skeletal muscle myopathy, growth retardation, and neutropenia [88]. BTHS is caused by mutations in the TAZ gene, which encodes a transacylase involved in the remodeling of phospholipids [89]. The lipid composition of cells from patients with BTHS shows a dramatic decrease in CL levels and reduced incorporation of linoleic acid (18:2) into CL and its precursor phosphatidylglycerol, even though their biosynthetic capacity to synthesize CL remains unchanged [90,91]. In addition, TLCL, the most predominant CL species in mitochondria from the skeletal and heart muscles, is almost completely absent in BTHS [92]. The mitochondria of BTHS patients exhibit abnormal ultrastructure and respiratory chain defects in the muscles and fibroblasts [88,93,94]. In support of the causative role of ALCAT1 in mitochondrial dysfunction in BTHS, ALCAT1 protein expression in the heart is upregulated by TAZ deficiency, whereas targeted deletion of ALCAT1 not only prevents cardiomyopathy, but also restores mitochondrial morphology and respiration without significant effects on TLCL levels in the hearts of a mouse model of inducible TAZ depletion.

7. Cancer

Aging is the major risk factor in the development of cancer since the majority of cancer incidences happen in people over the age of 60 [95]. Mitochondrial dysfunction plays a major role in the development of cancer. This notion is supported by the Warburg effect, which is defined as increased glucose uptake and preferential production of lactate [96]. Accordingly, mitochondria are involved in key steps of cancer aggressiveness, tumor growth, and metastasis. In contrast to its projected role in metabolic diseases, little is known about the regulatory function of CL in the development of cancer. Although the dysregulation of CL metabolism has been observed in several types of cancer, much of the evidence remains correlative and ambiguous [97,98]. For example, CL synthesis is implicated in tumor suppression, since mRNA expression level of cardiolipin synthase gene is positively correlated with the survival rate of patients with non-small cell lung cancer (NSCLC) [99]. In contrast, CL remodeling by TAZ has been reported to promote growth and survival of thyroid and cervical cancer cells, suggesting that the role of CL is cancer type-dependent [100,101].
Hypoxia plays a major role in cancer cell metastasis by stimulating the angiogenesis of blood vessels. Consistent with this notion, inhibition of angiogenesis by VEGF inhibitors has been used as a popular treatment for various types of cancers [102]. Consistent with its projected role in age-related diseases, CL remodeling by ALCAT1 potentially controls all aspects of cancer development, growth, and metastasis by promoting Warburg effect, oxidative stress, mitochondrial dysfunction, and angiogenesis. In support of this hypothesis, the overexpression of ALCAT1 led to the Warburg effect, including increased production of lactate and mitochondrial dysfunction [18]. Additionally, ALCAT1 is predominantly expressed in microvascular tissues in mammals and controls the generation of hematopoietic and endothelial lineages in zebrafish [64,103]. Consequently, the inactivation of ALCAT1 in zebrafish prevented the development of blood vessels [103]. Furthermore, ALCAT1 also mediated hypoxic responses, as shown by a recent report [17]. In direct support of the role of ALCAT1 in cancer, a recent report showed that upregulated ALCAT1 expression played a critical role in the development of NSCLC. Accordingly, the ALCAT1 expression level was negatively correlated with the survival rate of NSCLC patients, whereas inhibition of ALCAT1 by a mimetic peptide significantly attenuated cancer cell migration, leading to significant improvement in the survival of mice with NSCLC [65].

8. Conclusion

How aging promotes the development of various age-related diseases is one of the frontiers of biological research. The current evidences support a unified theory on CL remodeling by ALCAT1 as the root cause of age-related diseases by controlling mitochondrial etiology of these disorders (Figure 2). Although much of the evidences accumulated thus far come from studies on mouse models of age-related diseases, the latest development of potent and selective ALCAT1 inhibitors has made it possible to test this theory in human patients in the near future.

Figure 2. ALCAT1 controls mitochondrial etiology of age-related diseases in response to oxidative stress. ALCAT1 expression is upregulated by ROS from oxidative stress associated with age-related diseases. CL remodeling with PUFA by ALCAT1 causes CL peroxidation, leading to a vicious cycle of ROS production, CL peroxidation, and mitochondrial dysfunction which promote the development of age-related metabolic diseases.

References

  1. Sparagna, G.C.; Chicco, A.J.; Murphy, R.C.; Bristow, M.R.; Johnson, C.A.; Rees, M.L.; Maxey, M.L.; McCune, S.A.; Moore, R.L. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J. Lipid Res. 2007, 48, 1559–1570.
  2. Jia, D.; Zhang, J.; Nie, J.; Andersen, J.P.; Rendon, S.; Zheng, Y.; Liu, X.; Tian, Z.; Shi, Y. Cardiolipin Remodeling by ALCAT1 Links Hypoxia to Coronary Artery Disease by Promoting Mitochondrial Dysfunction. Mol. Ther. 2021.
  3. Li, J.; Romestaing, C.; Han, X.; Li, Y.; Hao, X.; Wu, Y.; Sun, C.; Liu, X.; Jefferson, L.S.; Xiong, J.; et al. Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. Cell Metabolism. 2010, 12, 154–165.
  4. Han, X.; Yang, J.; Cheng, H.; Yang, K.; Abendschein, D.R.; Gross, R.W. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry 2005, 44, 16684–16694.
  5. Schlame, M.; Horvath, L.; Vigh, L. Relationship between lipid saturation and lipid-protein interaction in liver mitochondria modified by catalytic hydrogenation with reference to cardiolipin molecular species. Biochem. J. 1990, 265, 79–85.
  6. Yamaoka-Koseki, S.; Urade, R.; Kito, M. Cardiolipins from rats fed different dietary lipids affect bovine heart cytochrome c oxidase activity. J. Nutr. 1991, 121, 956–958.
  7. Nomura, K.; Imai, H.; Koumura, T.; Kobayashi, T.; Nakagawa, Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. Biochem. J. 2000, 351, 183–193.
  8. Hostetler, K.Y.; Galesloot, J.M.; Boer, P.; Van Den Bosch, H. Further studies on the formation of cardiolipin and phosphatidylglycerol in rat liver mitochondria. Effect of divalent cations and the fatty acid composition of CDP-diglyceride. Biochim. Biophys. Acta. 1975, 380, 382–389.
  9. Rustow, B.; Schlame, M.; Rabe, H.; Reichmann, G.; Kunze, D. Species pattern of phosphatidic acid, diacylglycerol, CDP-diacylglycerol and phosphatidylglycerol synthesized de novo in rat liver mitochondria. Biochim. Biophys. Acta. 1989, 1002, 261–263.
  10. Schlame, M.; Rustow, B.; Kunze, D.; Rabe, H.; Reichmann, G. Phosphatidylglycerol of rat lung. Intracellular sites of formation de novo and acyl species pattern in mitochondria, microsomes and surfactant. Biochem. J. 1986, 240, 247–252.
  11. Chen, D.; Zhang, X.-Y.; Shi, Y. Identification and functional characterization of hCLS1, a human cardiolipin synthase localized in mitochondria. Biochem. J. 2006, 398, 169–176.
  12. Houtkooper, R.H.; Akbari, H.; van Lenthe, H.; Kulik, W.; Wanders, R.J.A.; Frentzen, M.; Vaz, F.M. Identification and characterization of human cardiolipin synthase. FEBS Lett. 2006, 580, 3059–3064.
  13. Lu, B.; Xu, F.Y.; Jiang, Y.J.; Choy, P.C.; Hatch, G.M.; Grunfeld, C.; Feingold, K.R. Cloning and characterization of a cDNA encoding human cardiolipin synthase (hCLS1). J. Lipid Res. 2006, 47, 1140–1145.
  14. Shi, Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. J. Biomed. Res. 2010, 24, 6–15.
  15. Mejia, E.M.; Hatch, G.M. Mitochondrial phospholipids: Role in mitochondrial function. J. Bioenerg. Biomembr. 2016, 48, 99–112.
  16. Claypool, S.M.; Koehler, C.M. The complexity of cardiolipin in health and disease. Trends Biochem. Sci. 2012, 37, 32–41.
  17. Schlame, M.; Rua, D.; Greenberg, M.L. The biosynthesis and functional role of cardiolipin. Prog. Lipid Res. 2000, 39, 257–288.
  18. Xu, Y.; Kelley, R.I.; Blanck, T.J.J.; Schlame, M. Remodeling of cardiolipin by phospholipid transacylation. J. Biol. Chem. 2003, 278, 51380–51385.
  19. Cao, J.; Liu, Y.; Lockwood, J.; Burn, P.; Shi, Y. A novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA:lysocardiolipin acyltransferase (ALCAT1) in mouse. J. Biol. Chem. 2004, 279, 31727–31734.
  20. Taylor, W.A.; Hatch, G.M. Purification and characterization of monolysocardiolipin acyltransferase from pig liver mitochondria. J. Biol. Chem. 2003, 278, 12716–12721.
  21. Taylor, W.A.; Hatch, G.M. Identification of the human mitochondrial linoleoyl-coenzyme A monolysocardiolipin acyltransferase (MLCL AT-1). J. Biol. Chem. 2009, 284, 30360–30371.
  22. Taylor, W.A.; Mejia, E.M.; Mitchell, R.W.; Choy, P.C.; Sparagna, G.C.; Hatch, G.M. Human trifunctional protein alpha links cardiolipin remodeling to beta-oxidation. PLoS ONE 2012, 7, e48628.
  23. Liu, X.; Ye, B.; Miller, S.; Yuan, H.; Zhang, H.; Tian, L.; Nie, J.; Imae, R.; Arai, H.; Li, Y.; et al. Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy. Mol. Cell Biol. 2012, 32, 4493–4504.
  24. Song, C.; Zhang, J.; Qi, S.; Liu, Z.; Zhang, X.; Zheng, Y.; Andersen, J.P.; Zhang, W.; Strong, R.; Martinez, P.A.; et al. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases. Aging Cell 2019, 18, e12941.
  25. Wang, L.; Liu, X.; Nie, J.; Zhang, J.; Kimball, S.R.; Zhang, H.; Zhang, W.J.; Jefferson, L.S.; Cheng, Z.; Ji, Q.; et al. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis. Hepatology 2015, 61, 486–496.
  26. Anderson, E.J.; Kypson, A.P.; Rodriguez, E.; Anderson, C.A.; Lehr, E.J.; Neufer, P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol. 2009, 54, 1891–1898.
  27. Bonnard, C.; Durand, A.; Peyrol, S.; Chanseaume, E.; Chauvin, M.-A.; Morio, B.; Vidal, H.; Rieusset, J. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J. Clin. Investig. 2008, 118, 789–800.
  28. Furukawa, S.; Fujita, T.; Shimabukuro, M.; Iwaki, M.; Yamada, Y.; Nakajima, Y.; Nakayama, O.; Makishima, M.; Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investig. 2004, 114, 1752–1761.
  29. Houstis, N.; Rosen, E.D.; Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440, 944–948.
  30. Evans, J.L.; Goldfine, I.D.; Maddux, B.A.; Grodsky, G.M. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23, 599–622.
  31. Li, J.; Liu, X.; Wang, H.; Zhang, W.; Chan, D.C.; Shi, Y. Lysocardiolipin acyltransferase 1 (ALCAT1) controls mitochondrial DNA fidelity and biogenesis through modulation of MFN2 expression. Proc. Natl. Acad. Sci. USA 2012, 109, 6975–6980.
  32. Ziaeian, B.; Fonarow, G.C. Epidemiology and Etiology of heart failure. Nat. Rev. Cardiol. 2016, 13, 368–378.
  33. Doenst, T.; Nguyen, T.D.; Abel, E.D. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ. Res. 2013, 113, 709–724.
  34. Tocchi, A.; Quarles, E.K.; Basisty, N.; Gitari, L.; Rabinovitch, P.S. Mitochondrial dysfunction in cardiac aging. Biochim. Biophys. Acta 2015, 1847, 1424–1433.
  35. Pangborn, M.C. Isolation and purification of a serologically active phospholipid from beef heart. J. Biol. Chem. 1942, 143, 247–256.
  36. Chicco, A.J.; Sparagna, G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 2007, 292, C33–C44.
  37. Hsu, P.; Shi, Y. Regulation of autophagy by mitochondrial phospholipids in health and diseases. Biochim. Biophys. Acta 2016.
  38. Lee, H.-J.; Mayette, J.; Rapoport, S.I.; Bazinet, R.P. Selective remodeling of cardiolipin fatty acids in the aged rat heart. Lipids Health Dis. 2006, 5, 2.
  39. Watkins, S.M.; Carter, L.C.; German, J.B. Docosahexaenoic acid accumulates in cardiolipin and enhances HT-29 cell oxidant production. J. Lipid Res. 1998, 39, 1583–1588.
  40. Ng, Y.; Barhoumi, R.; Tjalkens, R.B.; Fan, Y.Y.; Kolar, S.; Wang, N.; Lupton, J.R.; Chapkin, R.S. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 2005, 26, 1914–1921.
  41. Han, X.; Yang, J.; Yang, K.; Zhao, Z.; Abendschein, D.R.; Gross, R.W. Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: A shotgun lipidomics study. Biochemistry 2007, 46, 6417–6428.
  42. Sparagna, G.C.; Lesnefsky, E.J. Cardiolipin remodeling in the heart. J. Cardiovasc. Pharmacol. 2009, 53, 290–301.
  43. Paradies, G.; Petrosillo, G.; Paradies, V.; Ruggiero, F.M. Oxidative stress, mitochondrial bioenergetics, and cardiolipin in aging. Free Radic. Biol. Med. 2010, 48, 1286–1295.
  44. Paradies, G.; Petrosillo, G.; Paradies, V.; Ruggiero, F.M. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium 2009, 45, 643–650.
  45. Wang, W.; Ni, L.; Yu, Q.; Xiong, J.; Liu, H.C.; Rosenwaks, Z. Expression of the Lycat gene in the mouse cardiovascular and female reproductive systems. Dev. Dyn. 2010, 239, 1827–1837.
  46. Wang, W.; Zhao, F.; Ma, X.; Perry, G.; Zhu, X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances. Mol. Neurodegener. 2020, 15, 30.
  47. Abou-Sleiman, P.M.; Muqit, M.M.; Wood, N.W. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat. Rev. Neurosci. 2006, 7, 207–219.
  48. Agrawal, I.; Jha, S. Mitochondrial Dysfunction and Alzheimer’s Disease: Role of Microglia. Front. Aging Neurosci. 2020, 12.
  49. Kiebish, M.A.; Han, X.; Cheng, H.; Chuang, J.H.; Seyfried, T.N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: Lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 2008, 49, 2545–2556.
  50. Ellis, C.E.; Murphy, E.J.; Mitchell, D.C.; Golovko, M.Y.; Scaglia, F.; Barcelo-Coblijn, G.C.; Nussbaum, R.L. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell Biol. 2005, 25, 10190–10201.
  51. Bayir, H.; Tyurin, V.A.; Tyurina, Y.Y.; Viner, R.; Ritov, V.B.; Amoscato, A.A.; Zhao, Q.; Zhang, X.J.; Janesko-Feldman, K.L.; Alexander, H.; et al. Selective early cardiolipin peroxidation after traumatic brain injury: An oxidative lipidomics analysis. Ann. Neurol. 2007, 62, 154–169.
  52. Ryan, T.; Bamm, V.V.; Stykel, M.G.; Coackley, C.L.; Humphries, K.M.; Jamieson-Williams, R.; Ambasudhan, R.; Mosser, D.D.; Lipton, S.A.; Harauz, G.; et al. Cardiolipin exposure on the outer mitochondrial membrane modulates α-synuclein. Nat. Commun. 2018, 9, 817.
  53. Barth, P.G.; Valianpour, F.; Bowen, V.M.; Lam, J.; Duran, M.; Vaz, F.M.; Wanders, R.J. X- linked cardioskeletal myopathy and neutropenia (Barth syndrome): An update. Am. J. Med. Genet. Part. A 2004, 126, 349–354.
  54. Neuwald, A.F. Barth syndrome may be due to an acyltransferase deficiency. Curr. Biol. 1997, 7, R465–R466.
  55. Barth, P.G.; Scholte, H.R.; Berden, J.A.; Van der Klei-Van Moorsel, J.M.; Luyt-Houwen, I.E.; Van ‘t Veer-Korthof, E.T.; Van der Harten, J.J.; Sobotka-Plojhar, M.A. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J. Neurol. Sci. 1983, 62, 327–355.
  56. Vreken, P.; Valianpour, F.; Nijtmans, L.G.; Grivell, L.A.; Plecko, B.; Wanders, R.J.; Barth, P.G. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem. Biophys. Res. Commun. 2000, 279, 378–382.
  57. Schlame, M.; Towbin, J.A.; Heerdt, P.M.; Jehle, R.; DiMauro, S.; Blanck, T.J. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann. Neurol. 2002, 51, 634–637.
  58. Bissler, J.J.; Tsoras, M.; Goring, H.H.; Hug, P.; Chuck, G.; Tombragel, E.; McGraw, C.; Schlotman, J.; Ralston, M.A.; Hug, G. Infantile dilated X-linked cardiomyopathy, G4.5 mutations, altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal muscle. Lab. Investig. 2002, 82, 335–344.
  59. Zhang, J.; Liu, X.; Nie, J.; Shi, Y. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome. Autophagy 2022, 1–16.
  60. Fane, M.; Weeraratna, A.T. How the ageing microenvironment influences tumour progression. Nat. Rev. Cancer 2020, 20, 89–106.
  61. DeBerardinis, R.J.; Chandel, N.S. We need to talk about the Warburg effect. Nat. Metab. 2020, 2, 127–129.
  62. Ahmadpour, S.T.; Mahéo, K.; Servais, S.; Brisson, L.; Dumas, J.-F. Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer. Int. J. Mol. Sci. 2020, 21, 8031.
  63. Zhong, H.; Xiao, M.; Zarkovic, K.; Zhu, M.; Sa, R.; Lu, J.; Tao, Y.; Chen, Q.; Xia, L.; Cheng, S.; et al. Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: A novel link between oxidative stress and cancer. Free. Radic. Biol. Med. 2017, 102, 67–76.
  64. Feng, H.M.; Zhao, Y.; Zhang, J.P.; Zhang, J.H.; Jiang, P.; Li, B.; Wang, C. Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer. Oncol. Lett. 2018, 15, 2661–2668.
  65. Pathak, S.; Meng, W.J.; Zhang, H.; Gnosa, S.; Nandy, S.K.; Adell, G.; Holmlund, B.; Sun, X.F. Tafazzin protein expression is associated with tumorigenesis and radiation response in rectal cancer: A study of Swedish clinical trial on preoperative radiotherapy. PLoS ONE 2014, 9, e98317.
  66. Li, X.; Wu, M.; An, D.; Yuan, H.; Li, Z.; Song, Y.; Liu, Z. Suppression of Tafazzin promotes thyroid cancer apoptosis via activating the JNK signaling pathway and enhancing INF2- mediated mitochondrial fission. J. Cell Physiol. 2019.
  67. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2, 795–803.
  68. Xiong, J.-W.; Yu, Q.; Zhang, J.; Mably, J.D. An acyltransferase controls the generation of hematopoietic and endothelial lineages in zebrafish. Circ. Res. 2008, 102, 1057–1064.
  69. Huang, L.S.; Kotha, S.R.; Avasarala, S.; VanScoyk, M.; Winn, R.A.; Pennathur, A.; Yashaswini, P.S.; Bandela, M.; Salgia, R.; Tyurina, Y.Y.; et al. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J. Biol. Chem. 2020, 295, 13393–13406.
More